Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 14, 2018 - Issue 4
Submit an article Journal homepage
1,631
Views
2
CrossRef citations to date
0
Altmetric
Research Paper

Trends involving monoclonal antibody (mAb) research and commercialization: A scientometric analysis of IMS Lifecycle R&D Focus Database (1980–2016)

Yunfeng LaiState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, ChinaView further author information
,
Sizhuo SuoState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, ChinaView further author information
,
Ruibing WangState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, ChinaView further author information
,
Xiangjun KongState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, ChinaView further author information
,
Yuanjia HuState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, ChinaView further author information
,
Daisheng TangSchool of Economics and Management, Beijing Jiaotong University, Beijing, ChinaView further author information
,
Honghao ShiState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, ChinaView further author information
,
Shengqi ChenState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, ChinaView further author information
&
Hao HuState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 847-855 | Received 21 Jul 2017, Accepted 16 Dec 2017, Published online: 23 Jan 2018

References

  • Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer. 2015;15:361-70. PMID:25998715. doi:10.1038/nrc3930
  • Liu JKH. The history of monoclonal antibody development: Progress, remaining challenges and future innovations. Ann Med Surg. 2014;3(4):113-6. doi:10.1016/j.amsu.2014.09.001
  • Shepard HM, Phillips GL, Thanos CD, Feldmann M. Development in therapy with monoclonal antibodies and related proteins. Clin Med. 2017;17(3): 220-232. doi:10.7861/clinmedicine.17-3-220
  • Firestone Inventing. The global map of Monoclonal antibody drugs 2016 Report. Hangzhou, China: Firestone; 2016. Available at: http://www.hsmap.com/precision_medical_detail.html?pm_child = % E6%8A%97%E4%BD%93%E8%8D%AF%E7%89%A9&report_id = 115&report_name = %E7%81%AB%E7%9F%B3%E5%8F%91%E5%B8%83-%E6%8A%97%E4%BD%93%E8%8D%AF%E7%89%A9%E5%85%A8%E7%90%83%E5%9C%B0%E5%9B%BE
  • Kennedy PJ, Oliveira C, Granja PL, Sarmento B. Monoclonal antibodies: technologies for early discovery and engineering. Crit Rev Biotechnol. 2017;1-15. doi:10.1080/07388551.2017.1357002
  • Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal anti- body market. MAbs. 2015;7(1):9-14. PMID:25529996. doi:10.4161/19420862.2015.989042
  • Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12:278-87. PMID:22437872. doi:10.1038/nrc3236
  • Rimawi MF, Schiff R, Osborne C. Targeting HER2 for the treatment of breast cancer. Annu Rev Med. 2015;66:111-128. doi:10.1146/annurev-med-042513-015127.
  • Lavaud P, Andre F. Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. BMC Med. 2014;12:132. doi:10.1186/s12916-014-0132-3.
  • Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Bio. 2001;2:127-37. doi:10.1038/35052073.
  • Ecker DM, Ransohoff TC, Jones SD, Levine HL. The state of mammalian cell culture biomanufacturing. Woburn (MA): BioProcess Technology Consultants, Inc; 2011 Dec 12; 150 p. Available at: http://www.bptc.com/Ecommerce/Reports.
  • DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 2010;87(3):272-277. doi:10.1038/clpt.2009.295
  • Pavlou AK, Reichert JM. Recombinant protein therapeutics-success rates, market trends and values to 2010. Nat Biotechnol. 2004;22(12):1513-1519; doi:10.1038/nbt1204-1513
  • Geng XM, Kong XJ, Hu H, Chen JY, Yang FQ, Liang HU, Chen X, Hu YJ. Research and development of therapeutic mAbs: an analysis based on pipeline projects. Hum Vacc Immunother. 2015;11(12):2769-2776. doi:10.1080/21645515.2015.1074362
  • Kong XJ, Wan JB, Hu H, Su SB, Hu YJ. Evolving patterns in a collaboration network of global R&D on monoclonal antibodies. MABS. 2017;0(0):1-11. doi:10.1080/19420862.2017.1356527
  • Chen CM. CiteSpace II: Detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inf Sci Tech- nol. 2006;57(3):359-77. doi:10.1002/asi.20317
  • Chen CM, Hu ZG, Liu SB, Tseng H. Emerging trends in regenerative medicine: a scientometric analysis in CiteSpace. Expert Opin Biol Ther. 2012;12(5):593-608. PMID:22443895. doi:10.1517/14712598.2012.674507
  • Chen CM, Dubin R, Kim MC. Emerging trends and new developments in regenerative medicine: a scientometric update (2000-2014). Expert Opin Biol Ther. 2014;14(9):1295-17. PMID:25077605. doi:10.1517/14712598.2014.920813
  • Lai YF, Wang RB, Chen X, Tang DS, Hu YJ, Cai J, Zhang QW, Hu H. Emerging trends and new developments in monoclonal antibodies: A scientometric analysis (1980-2016). Hum Vacc Immunother. 2017;13(6):1388-1397. doi:10.1080/21645515.2017.1286433
  • Duan LM, Du YP, Meng L. An empirical research on the factors influencing the commercialization's performance of emerging technology. Studies in Science of Science. 2012;30(9):1354-1362. doi:10.16192/j.cnki.1003-2053.2012.09.010
  • Youtie J, Hicks D, Shapira P, Horsley T. Pathways from discovery to commercialization: using web sources to track small and medium-sized enterprise strategies in emerging nanotechnologies. Technol Anal Strateg. 2012;24(10):981-995. doi:10.1080/09537325.2012.724163
  • Shapira P, Youtie J, Arora S. Early patterns of commercial activity in graphene. J Nanopart Res. 2012;14:811. doi:10.1007/s11051-012-0811-y
  • He XL, Qian Q, Zhang Z. Visualization: based analysis of tumor epidemical data. Chin J Med Libr Inf Sci. 2016;25(1):73-80. doi:10.3969/j.issn.1671-3982.2016.01.016

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.